Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

FDA Approval of Brigatinib for ALK+ NSCLC

April 27th 2017

Patterns of Progression on Crizotinib for ALK+ NSCLC

April 27th 2017

The Evolution of ALK/ROS1-Targeted Therapy in NSCLC

April 27th 2017

EU Grants Full Approval to Osimertinib for EGFR T790M-Positive NSCLC

April 27th 2017

The European Union has granted a full approval to osimertinib (Tagrisso) for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive non–small cell lung cancer, regardless of prior treatment with an EGFR TKI.

Biomarker Testing in NSCLC to Expand in Near Future

April 26th 2017

Matthew Gubens, MD, discusses how far the field of NSCLC has come with molecular testing, the challenges still ahead, and what novel assays could be on the horizon.

Dr. Socinski on Improvements to Immunotherapy for Lung Cancer

April 26th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.

Immunotherapy Revolutionizes NSCLC, But Unanswered Questions Remain

April 25th 2017

Edward B. Garon, MD discusses the challenges researchers are currently facing with immunotherapy in NSCLC and what the future likely holds for the pivotal agents.

Emerging Biomarkers in Lung Cancer

April 24th 2017

Emerging Data in EGFR-Mutant Lung Cancer

April 24th 2017

Osimertinib in T790M-Mutant Lung Cancer

April 24th 2017

Resistance in EGFR-Mutant Lung Cancer

April 24th 2017

Treating Beyond Progression in EGFR-Mutant Lung Cancer

April 24th 2017

EGFR-Mutant Lung Cancer: Initial Approach

April 24th 2017

Role for Plasma-Based Testing in Lung Cancer

April 24th 2017

Molecular Testing in Lung Cancer

April 24th 2017

Multidisciplinary Approaches in Lung Cancer

April 24th 2017

Diagnostic Workup in Lung Cancer: A Focus on Pathology

April 24th 2017

Understanding EGFR-Mutant NSCLC Subsets

April 24th 2017

Mutation Testing in NSCLC

April 24th 2017

Dr. Farago on Combination of Olaparib and Temozolomide in Small Cell Lung Cancer

April 24th 2017

Anna Farago, MD, PhD, assistant, Medicine, Massachusetts General Hospital Cancer Center, and instructor, Medicine, at Harvard Medical School, discusses the combination of olarparib (Lynparza) and temozolomide (Temodar) for patients with small cell lung cancer (SCLC).